Accomplishments of Dr. JeanMarie Guenot in the Biotechnology and Pharmaceutical Industry



JeanMarie Guenot has built a remarkable professional career and continues to make a difference in the biotechnology and pharmaceutical industry. Her accomplishments include the discovery and development of various drugs, building companies, and negotiating merger & acquisition transactions for PDL’s R&D. After earning a Ph.D. from the University of California in San Francisco, she received training in physical and medicinal chemistry. Guenot started her career immediately after training in drug design, x-ray refinement, predicting protein structure, and molecular dynamics methods.



As per Linked In, Dr. Guenot’s professional career began at Atlas Venture managing capital investments and building life science companies. She later pursued a career as a scientist at Hoffmann-La Roche in Preclinical Research & Development creating drugs for treatments. The drugs are used for oncology and inflammation treatments, and to treat diseases, including autoimmune and metabolic. Dr. Guenot joined Hoffmann-La Roche as a business advisor in Shanghai and Basel and eventually joined PDL BioPharma as Vice-President.



While serving as vice president of Corporate & Business Development at PDL, she had significant executive responsibilities. Dr. Guenot was in charge of mergers & acquisitions, alliance management, negotiations, licensing, and leading the development team. The Biogen Idec-PDL 50:50 Co-development and co-commercialization collaboration transaction net worth is $800 million with $100 million of equity invested in PDL. She managed the company’s commercial product portfolios and successfully licensed an oncology drug’s ophthalmic indication to Ophthotech.



Presently, Dr. JeanMarie Guenot is the Chief Executive Officer and President of Amphivena Therapeutics, Inc., a bi-functional antibody therapeutic development company. You can find Dr. Guenot’s page on the Amphivena website here. She oversees the operations of researching and developing therapy to cure blood cancers by destroying tumor cells. Before joining Amphivena, Dr. Guenot became an entrepreneur and established SKSOcular, an ophthalmic company specializing in therapeutics, and drug technologies. She continues to demonstrate excellence as a leader, scientist, researcher, and executive. Her accomplishments prove her ability to lead, build strong companies, and develop therapy.